MedDataX Logo

Ax-003/Arimidex (Anastrozole) in the Adjuvant Therapy of Early Breast Cancer

NCT ID: NCT00638391

Last Updated: 2008-03-20

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

1600 participants

Study Classification

OBSERVATIONAL

Study Start Date

2005-05-31

Study Completion Date

2007-03-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is the initial/followed by 5 year adjuvant therapy with Anastrozole.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Secondary Adjuvant Long Term Study With Arimidex

NCT00295620

Breast Cancer
COMPLETED PHASE3

Non-interventional Study to Evaluate Arimidex in Postmenopausal Women With Advanced Breast Cancer

NCT00562458

Advanced Breast Cancer
COMPLETED

3 Years of Anastrozole vs. no Treatment as Extended Adjuvant Therapy for Postmenopausal Women With Breast Cancer

NCT00300508

Breast Neoplasms
COMPLETED PHASE3

Anastrozole and Fulvestrant Compared to Anastrozole as Adjuvant Treatment of Postmenopausal Patients With Breast Cancer

NCT00357110

Breast Cancer
COMPLETED PHASE2

An Observational Study of Adherence to Anastrozole in Early Breast Cancer Treatment

NCT00737009

Breast Cancer
COMPLETED

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Breast Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_ONLY

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

1

all patients treated with Anastrozole

Anastrozole

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Anastrozole

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Arimidex

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Postmenopausal women with early hormone receptor positive breast cancer/no metastasis

Exclusion Criteria

* None
Eligible Sex

FEMALE

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

AstraZeneca

INDUSTRY

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

AstraZeneca

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

H Brasch

Role: STUDY_DIRECTOR

AstraZeneca Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

Ax-003/Arimidex

Identifier Type: -

Identifier Source: secondary_id

Ax-003

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Letrozole as Early Adjuvant Treatment of Postmenopausal Patients With Primary Breast Cancer
NCT00332852 COMPLETED PHASE3
Arthralgia During Anastrozole Therapy for Breast Cancer
NCT00323479 COMPLETED PHASE4
Different Durations of Adjuvant Anastrozole Therapy After 2 to 3 Years Tamoxifen Therapy in Breast Cancer
NCT00301457 COMPLETED PHASE3
Study on Pre-menopausal Patients With Advanced ER and PR + BC Treated With Arimidex Plus Zoladex
NCT00235937 COMPLETED PHASE2
Effectiveness of Combination of Arimidex and Nolvadex in Adjuvant Therapy of Breast Carcinoma in Postmenopausal Women.
NCT00287534 COMPLETED PHASE2
Study of Anastrozole +/- AZD8931 in Postmenopausal Women With Endocrine Therapy Naive Breast Cancer
NCT01151215 TERMINATED PHASE2
Comparing Anastrozole-Placebo to the Combination Anastrozole-ZD1839 in Postmenopausal Patients With Estrogen Receptor and/or Progesterone Receptor Metastatic Breast Cancer
NCT00077025 COMPLETED PHASE2
Survey Conducted Among Early Breast Cancer Patients Treated With Arimidex for Evaluation of Treatment Adherence
NCT01081509 COMPLETED
Survey in Post-menopausal Women Followed up After Treatment With Anastrozole as Adjuvant Therapy
NCT00542594 TERMINATED
Anastrozole in Preventing Breast Cancer in Postmenopausal Women at Increased Risk of Breast Cancer
NCT00078832 COMPLETED PHASE3
Anastrozole With or Without Gefitinib in Treating Postmenopausal Women With Metastatic or Locally Recurrent Breast Cancer
NCT00066378 COMPLETED PHASE2
Gene Expression Following Short Term Exposure to Neoadjuvant Endocrine Therapy in Invasive Breast Cancer
NCT00588003 COMPLETED PHASE1
CONcurrent vs SEqueNTial Adjuvant Treatments in Early Breast Cancer
NCT02918084 ACTIVE_NOT_RECRUITING PHASE3
Breast Cancer Tumor Care Observational Programme
NCT00660244 COMPLETED
Arimidex/Tamoxifen Neo Adjuvant Study in Premenopausal Patients With Breast Cancer Under Anti Hormonal Treatment
NCT00605267 COMPLETED PHASE3
Raloxifene and Goserelin in Preventing Breast Cancer in Women With a Family History of Breast Cancer
NCT00031850 COMPLETED NA
Estradiol Suppression for the Treatment of Metastatic Breast Cancer in Premenopausal Women
NCT00186121 COMPLETED PHASE2
Chemoprevention Trial - Anastrozole in Ductal Carcinoma In Situ (DCIS) in Postmenopausal Women
NCT00256217 COMPLETED PHASE2
CDK4/6 Inhibitors Combined With Standard Adjuvant Endocrine Therapy in High-Risk, HR+/HER2+ Early Breast Cancer Patients(CHESS)
NCT07019363 RECRUITING PHASE3
This is a Multicenter, Randomized, Double-blind, Placebo-controlled Phase III Clinical Study Evaluating the Efficacy and Safety of FCN-437c Versus Placebo in Combination With Letrozole or Anastrozole ± Goserelin in Women With HR+ and HER2- Advanced Breast Cancer.
NCT05439499 UNKNOWN PHASE3
Letrozole in Treating Postmenopausal Women Who Have Received Hormone Therapy for Hormone Receptor-Positive Breast Cancer
NCT00382070 ACTIVE_NOT_RECRUITING PHASE3
A Study of Nonsteroidal Aromatase Inhibitors Plus Abemaciclib (LY2835219) in Postmenopausal Women With Breast Cancer
NCT02246621 ACTIVE_NOT_RECRUITING PHASE3
Anastrozole Monotherapy Versus Maximal Oestrogen Blockade With Anastrozole and Fulvestrant Combination Therapy
NCT00256698 COMPLETED PHASE3
Adjuvant Hormone Therapy in Treating Women With Operable Breast Cancer
NCT00002460 UNKNOWN PHASE3
Radiotherapy - Anastrazole Concomitant : Evaluation of the Side Effects
NCT01183832 COMPLETED